ERBB2 and breast cancer: Similarly, de Groot et al. (2015) investigated whether fasting for 24 h before receiving (neo) adjuvant TAC-chemotherapy therapy and for a subsequent 24 h after completing therapy could reduce hematological toxicity in subjects with stage II and III HER2-negative BC, using γ-H2AX in peripheral blood mononuclear cells (PBMCs) as a proxy marker for chemotherapy toxicity in normal somatic cells.